Cardiol Therapeutics Inc - Ordinary Shares - Class A
CRDL - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$116.08M
Close$
$0.18
82.6% downside
Current Fair Value
82.6% downsideOvervalued by 82.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $116.08 Million |
|---|---|
| Enterprise Value | $90.10 Million |
| Earnings per Share | $-0.39 |
| Beta | 0.52 |
| Outstanding Shares | 114,935,371 |
Return
| Return on Equity | -152.53% |
|---|---|
| Return on Assets | -124.84% |
| Return on Invested Capital | -152.07% |
Valuation & Multiples
| P/E Ratio | -4.71 |
|---|---|
| PEG | -136.41 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.46 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.09
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.36%▼ 25.32% |
|---|---|
| Total Invested | $690,535▼ 97.79% |
| Investors Holding | 4▼ 51.00% |
About Cardiol Therapeutics Inc
18 employees
CEO: David G. Elsley
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. It...